<SEC-DOCUMENT>0001144204-18-052561.txt : 20181005
<SEC-HEADER>0001144204-18-052561.hdr.sgml : 20181005
<ACCEPTANCE-DATETIME>20181004173549
ACCESSION NUMBER:		0001144204-18-052561
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20180928
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20181005
DATE AS OF CHANGE:		20181004

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABEONA THERAPEUTICS INC.
		CENTRAL INDEX KEY:			0000318306
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				830221517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15771
		FILM NUMBER:		181108587

	BUSINESS ADDRESS:	
		STREET 1:		3333 LEE PARKWAY
		STREET 2:		SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75219
		BUSINESS PHONE:		2149055100

	MAIL ADDRESS:	
		STREET 1:		3333 LEE PARKWAY
		STREET 2:		SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75219

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PLASMATECH BIOPHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20140922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ACCESS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19960209

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHEMEX PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tv504285_8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(D) OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of report (Date of earliest event reported):
<B>September 28, 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>ABEONA THERAPEUTICS INC.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>Delaware</U></B></FONT></TD>
    <TD STYLE="width: 34%; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>001-15771</U></B></FONT></TD>
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>83-0221517</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of<BR>
 incorporation)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>1330 Avenue of the Americas, 33rd Floor,
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>New York, NY 10019 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices)
(Zip Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>(646) 813-4712</U></B><BR>
(Registrant&rsquo;s telephone number, including area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>N/A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see<I>&nbsp;</I>General
Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px; text-align: justify"></TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px; text-align: justify"></TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px; text-align: justify"></TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px; text-align: justify"></TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company&#9;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><FONT STYLE="font-size: 10pt"><B>Item 5.02.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Departure of Directors
or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</B></FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Abeona Therapeutics, Inc. (the &ldquo;<U>Company</U>&rdquo;),
previously announced that Jeffrey B. Davis was stepping down from his role as Chief Operating Officer at the end of the third quarter,
effective September 30, 2018. In connection with his resignation, on October 1, 2018, Mr. Davis entered into a letter agreement
with the Company confirming he will be entitled to receive certain salary continuation and other severance benefits. Under the
terms of the letter agreement, Mr. Davis will receive a prorated portion of his target bonus for 2018, a continuation of base salary
for forty-seven weeks, and a lump-sum payment equal to COBRA premiums that Mr. Davis would pay if he elected continued health coverage
under the Company&rsquo;s health plan. A copy of the letter agreement is filed herewith as Exhibit 10.1 to this Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">On
September 28, 2018, Stephen B. Thompson, the Company&rsquo;s Senior Vice President Finance and Administration,
Chief Accounting Officer (principal financial officer), Treasurer, and Secretary, notified the Company he will retire from
the Company on November 15, 2018, or such other date as may be mutually agreed. The Company has an ongoing search in process
for a Chief Financial Officer. </FONT>&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><B>Item 9.01</B></TD><TD STYLE="text-align: justify"><B>Financial Statements and Exhibits.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(d) Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0.85in; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt"><FONT STYLE="font-size: 10pt"><B><U>Exhibit No.</U></B></FONT></TD>
    <TD STYLE="width: 0.15in; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt"><FONT STYLE="font-size: 10pt"><B><U>Description</U></B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt"><A HREF="tv504285_ex10-1.htm"><FONT STYLE="font-size: 10pt">10.1</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt"><A HREF="tv504285_ex10-1.htm"><FONT STYLE="font-size: 10pt">Letter of Agreement and General Release dated October 1, 2018 between the Company and Jeffrey Davis</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 1pt solid"><B>SIGNATURE&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Abeona Therapeutics Inc.</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">(Registrant)</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; width: 50%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 4%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 5%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 31%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 10%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Stephen B. Thompson</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Stephen B. Thompson</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Title:&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Sr. Vice President Finance and Administration</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-top: 0; padding-right: 0; padding-bottom: 0; text-align: left">Chief Accounting Officer</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: October 4, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>tv504285_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;<IMG SRC="image_001.jpg" ALT=""></B></P>

<P STYLE="margin: 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>VIA ELECTRONIC MAIL AND HAND DELIVERY</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">October 1, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jeffrey Davis</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">36 Lake End Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Newfoundland, NJ 07435</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Jeffrey:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This letter of agreement and general release (&ldquo;Agreement&rdquo;)
confirms our mutual agreement regarding the terms and conditions of your separation from employment with Abeona Therapeutics, Inc.
(the &ldquo;Company&rdquo;). You and the Company agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD><B><U>Separation Date; Transition Period</U></B> - Provided you sign this Agreement, your effective date of separation from
the Company will be November 2, 2018 (the &ldquo;Separation Date&rdquo;), unless your employment is terminated earlier as addressed
below. The period between the date of this Agreement and the Separation Date will be a transition period (the &ldquo;Transition
Period&rdquo;), during which time you agree to reasonably assist the Company with the transition of your job duties and to perform
any other transition duties as may be reasonably requested by the Company (it being understood and agreed that such assistance
will not require any travel or a material amount of your time) (collectively, the &ldquo;Transition Duties&rdquo;). The Company
shall maintain, at the Company&rsquo;s cost and expense, your current level of benefits (health/medical and any other applicable
benefits) and salary at all times during the Transition Period.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD><B><U>Compensation/Severance Benefits</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>The Company will pay your current annual base salary through the Separation Date in accordance with the Company&rsquo;s usual
payroll guidelines and practices.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>On the next payroll date following the Separation Date, you will be paid an amount equal $98,438 in respect of to your prorated
target bonus for 2018.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD>You will further be paid for any accrued but unused vacation days, and will be reimbursed for previously submitted, but un-reimbursed,
business expenses in accordance with the Company&rsquo;s usual guidelines and practices.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD>Following your Separation Date, provided that: (i) you have satisfactorily performed the Transition Duties set forth in Paragraph
1 in all material respects</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="image_002.jpg" ALT=""></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">and complied with your other obligations
under this Agreement in all material respects (it being understood and agreed that the Company will provide you written notice
of any such non-compliance and that you will be deemed to have complied with any such obligations if you cure such non-compliance,
if curable, within five (5) days following the receipt of such notice); (ii) you have executed this Agreement on or before October
3, 2018, and you did not exercise your right to revoke during the 7-day revocation period specified in Paragraph 9; and (iii) you
execute a final release in a form substantially similar to Attachment A (the &ldquo;Final Release&rdquo;) on, and not before, the
Separation Date, and you do not exercise your right to revoke during the 7-day revocation period specified in Attachment A, in
consideration for your release and waiver of claims and other commitments set forth herein and in Attachment A:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD>The Company will pay you severance pay in the form of a forty-seven (47) week continuation of your base salary, less all applicable
state and federal taxes and withholdings. The severance pay will be paid as salary continuation in accordance with the Company&rsquo;s
normal payroll practices, but in no event shall payment begin prior to the Separation Date or earlier than the eighth (8th) day
after your execution and timely return of the Final Release.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD>The Company shall make a lump-sum payment within 30 days following the Separation Date equal to the COBRA premiums that you
would pay if you elected continued health coverage under the Company&rsquo;s health plan for you and your dependents for the 12-month
period following the Separation Date, based on the COBRA rates in effect at the Separation Date.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD>You will be entitled to receive your vested accrued benefits, if any, under the Company&rsquo;s 401(k) plan in accordance with
the terms and conditions of such plan.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">You will not be eligible for, nor shall you have a
right to receive, any payments from the Company following the Separation Date other than, as applicable, the amounts set forth
in subparagraphs (a), (b), (c), (d) and (e) above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD><B><U>Release</U> &ndash; </B>In consideration of your continued employment with the Company through the Transition Period
and your eligibility to receive payment of the severance benefits described in Paragraph 2, both of which you acknowledge you would
not otherwise be entitled to receive, you waive, subject to Paragraph 3a below, all claims available under federal, state or local
law against the Company and the directors, officers, employees, employee benefit plans and agents of the Company arising out of
your employment with the Company or the termination of that employment, including but not limited to all claims arising under the
Americans with Disabilities Act, the Age Discrimination in Employment Act, the Civil Rights Act of 1991, the Employee Retirement
Income Security Act (&ldquo;ERISA&rdquo;), the Equal Pay Act, the Genetic Information Non-discrimination Act, the Family and Medical
Leave Act, Section 1981 of U.S.C, Title VII of the Civil Rights Act; the New York State Human Rights Law, the New York State Executive
Law, the New York State Civil Rights Law, the retaliation provisions of the New York State Workers' Compensation Law, the New York
Labor Law, the New York City Human Rights Law, and the New York City Administrative Code; as well as wrongful termination claims,
breach of contract claims, discrimination claims, harassment claims, retaliation claims, whistleblower claims (to the fullest extent
they may be released under applicable law), defamation or other tort claims, and claims for attorneys&rsquo; fees and costs.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="image_002.jpg" ALT=""></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0"  STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">a.</TD><TD>The only claims not being waived, released and discharged by this Agreement are (i) those that relate to your rights and remedies
under this Agreement, (ii) any rights to indemnification exculpation and/or contribution to which you are entitled as of the date
hereof pursuant to the Company&rsquo;s and its affiliates organizational documents, any indemnification or similar agreement or
applicable law (and any rights under any insurance policies of the Company or its affiliates), and (iii) those that cannot be waived
as a matter of applicable law; any claims you may have to government-sponsored and administered benefits such as unemployment insurance,
workers&rsquo; compensation insurance (excluding claims for retaliation under workers&rsquo; compensation laws), state disability
insurance and paid family leave insurance benefits; and any benefits that vested on or prior to the Separation Date pursuant to
a written benefit plan sponsored by the Company and governed by the ERISA.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">b.</TD><TD>Nothing in this Agreement prevents you from filing a charge with, cooperating with, or participating in any proceeding before
the Equal Employment Opportunity Commission or a state fair employment practices agency (except that you acknowledge that you may
not recover any monetary benefits or personal relief in connection with any such claim, charge or proceeding).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">c.</TD><TD>You hereby represent that you have not instituted, assisted or otherwise participated in connection with, any action, complaint,
claim, charge, grievance, arbitration, lawsuit or administrative agency proceeding, or action at law or otherwise against the Company
or any other member of the Company or any of their respective shareholders, officers, employees, directors, shareholders or agents.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD><B><U>Post-Separation Obligations/Non-Disparagement</U></B> - Subject to Paragraph 5, you acknowledge and reaffirm your obligation
to keep confidential and not to disclose any and all non-public information concerning the Company that you acquired during the
course of your employment with the Company, including, but not limited to, any non-public information concerning the Company&rsquo;s
business affairs, business prospects and financial condition. You agree that you will not make any public statement intended to
disparage the Company. The Company agrees that it will not issue or authorize any public statement intended to disparage you.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="image_002.jpg" ALT=""></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0"  STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.</TD><TD><B><U>Disclosure Exceptions</U></B> - Nothing in this Agreement or the Final Release shall prohibit or restrict you from lawfully
(A) initiating communications directly with, cooperating with, providing information to, causing information to be provided to,
or otherwise assisting in an investigation by any governmental or regulatory agency, entity, or official(s) (collectively, &ldquo;Governmental
Authorities&rdquo;) regarding a possible violation of any law; (B) responding to any inquiry or legal process directed to you individually
(and not directed to the Company and/or its subsidiaries) from any such Governmental Authorities; (C) testifying, participating
or otherwise assisting in an action or proceeding by any such Governmental Authorities relating to a possible violation of law;
or (D) making any other disclosures that are protected under the whistleblower provisions of any applicable law. Additionally,
pursuant to the federal Defend Trade Secrets Act of 2016, you shall not be held criminally or civilly liable under any federal
or state trade secret law for the disclosure of a trade secret that: (a) is made (i) in confidence to a federal, state, or local
government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating
a suspected violation of law; or (b) is made to your attorney in relation to a lawsuit for retaliation against you for reporting
a suspected violation of law; or (c) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing
is made under seal. Nor does this Agreement require you to obtain prior authorization from the Company before engaging in any conduct
described in this paragraph, or to notify the Company that you have engaged in any such conduct.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.</TD><TD><B><U>Amendment</U></B> - This Agreement and the Final Release shall be binding upon the parties and may not be modified in
any manner, except by an instrument in writing of concurrent or subsequent date signed by the parties hereto or their duly authorized
representatives. This Agreement and the Final Release are binding upon and shall inure to the benefit of the parties and their
respective agents, assigns, heirs, executors, successors and administrators.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.</TD><TD><B><U>Confidentiality of this Agreement</U></B> - Subject to Paragraph 5, you understand and agree that in exchange for the
consideration set forth above, both during the Transition Period and thereafter, the terms and conditions of this Agreement, the
Final Release, and the contents of any negotiations and discussions resulting in this Agreement and the Final Release, shall be
maintained as confidential by you and your agents and representatives and shall not be disclosed to any third party except (i)
to the extent required by federal or state law or otherwise agreed to in writing by the Company or (ii) in connection with the
enforcement of your rights under this Agreement; provided that you and the Company shall be entitled to make third parties (including
your prospective employers) aware of this Agreement and your obligations under this Agreement (including those set forth in Paragraph
14 hereof).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">8.</TD><TD><B><U>Nature of Agreement</U></B> - You understand and agree that this Agreement and the Final Release represent a severance
agreement and do not constitute an admission of liability or wrongdoing on the part of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.</TD><TD><B><U>Acknowledgments </U></B>- You acknowledge that you are being provided at least twenty-one (21) days to consider this
Agreement, including all attachments hereto, and that the Company hereby advises you to consult with an attorney of your own choosing
prior to signing this Agreement. You understand that you may revoke this Agreement for a period of seven (7) days after execution,
and the Agreement shall not be effective or enforceable until the expiration of this seven (7) day period. You understand and agree
that by entering into this Agreement you are waiving any and all rights or claims you may have under the Age Discrimination in
Employment Act, as amended by the Older Workers Benefit Protection Act, and that you have received consideration beyond that to
which you were previously entitled. You agree that changes to this Agreement, whether material or immaterial, do not restart the
running of the 21-day consideration period.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="image_002.jpg" ALT=""></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0"  STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.</TD><TD><B><U>Taxes</U></B> &ndash; All payments hereunder will be subject to applicable deductions and withholdings. You shall bear
all expense of, and be solely responsible for, all federal, state and local taxes due with respect to any payment received under
this Agreement. This Agreement shall be interpreted to avoid any penalty sanctions under Section 409A of the Internal Revenue Code
(the &ldquo;<U>Code</U>&rdquo;). If any payment or benefit cannot be provided or made at the time specified herein without incurring
sanctions under Section 409A of the Code, then such benefit or payment shall be provided in full (to extent not paid in part at
earlier date) at the earliest time thereafter when such sanctions will not be imposed. For purposes of Section 409A of the Code,
all payments to be made upon a termination of employment under this Agreement may only be made upon the your &ldquo;separation
from service&rdquo; (within the meaning of such term under Section 409A of the Code) and each payment made under this Agreement
shall be treated as a separate payment. In no event shall you, directly or indirectly, designate the calendar year of payment,
except as permitted under Section 409A of the Code.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">11.</TD><TD><B><U>Further Cooperation</U> &ndash;</B> You agree that, during and after the term of this Agreement, you will make yourself
available, upon reasonable notice and under reasonable conditions, to assist the Company in any capacity with respect to matters
of which you were involved or had knowledge while employed by the Company. To that end, you agree to cooperate with the Company
in connection with any pending or future investigation or pending or threatened litigation matters, lawsuits or administrative
proceedings in which the Company believes you are an individual with knowledge concerning the subject thereof. In particular, but
without limitation, you agree to make yourself available for meetings, interviews, depositions, and court appearances, as reasonably
requested by the Company, and to otherwise reasonably assist the Company in connection with any such investigation or litigation,
or other proceedings. You also agree to provide the Company with any and all documents which may be in your possession that may
concern the subject matter of any pending or future investigation or litigation. You understand that the Company will reimburse
you for all reasonable, documented out-of-pocket expenses incurred as a result of my obligations under this paragraph in accordance
with the Company&rsquo;s then-applicable Expense Guidelines.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.</TD><TD><B><U>Exercise of Stock Options</U> &ndash; </B>You understand that you are not entitled to any future grants of stock or stock
options. In accordance with the Stock Option Agreement and Prospectus, you understand that up to and including the Separation Date,
all stock options that have vested as of the Separation Date, if any, must be exercised by the earlier of 12 months of the Separation
Date or the expiration of the option. You further understand that following the Separation Date, all stock options that vested
as of the Separation Date, if any, must be exercised within 12 months of the Separation Date. You further understand that upon
death or disability, all stock options that have vested as of the Separation Date, if any, must be exercised within twelve months
of said death or disability.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="image_002.jpg" ALT=""></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0"  STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">13.</TD><TD><B><U>Agreement Not to Seek Rehire</U> <I>&ndash;</I></B> You agree that, without prior written Company approval, you will
not seek or accept employment with the Company (including all subsidiaries and affiliates), including assignment to or on behalf
of the Company as an independent contractor or through any third party, and the Company has no obligation to consider you for any
future employment or assignment.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">14.</TD><TD><B><U>Restrictive Covenants</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD><B><U>Non-Competition</U></B> &ndash; In consideration for the promises made by the Company herein, you agree that you shall
not, during the 47 week period after the Separation Date (the &ldquo;Restriction Period&rdquo;), directly or indirectly, own, manage,
operate, join, control, be employed by, or participate in the ownership, management, operation or control of, or be connected in
any manner with, including, without limitation, holding any position as a stockholder, director, officer, consultant, independent
contractor, employee, partner, or investor in, any Restricted Enterprise (as defined below); provided, that in no event shall ownership
by you of two percent (2%) or less of the outstanding securities of any class of any issuer whose securities are registered under
the Securities Exchange Act of 1934, as amended, standing alone, be prohibited by this Paragraph 14, so long as you do not have,
or exercise, any rights to manage or operate the business of such issuer other than rights as a stockholder thereof. For purposes
of this paragraph, &ldquo;Restricted Enterprise&rdquo; shall mean any person or entity that, on the Separation Date, is engaged,
directly or indirectly, in a business of developing or commercializing biopharmaceutical therapies for those therapeutic indications
that the Company or its subsidiaries has either commercialized products or programs in pre-clinical or clinical development or
has undertaken material efforts to so engage on the Separation Date, in any country or territory in which on the Separation Date
the Company or any of its affiliates markets any of its services or products or has material plans to begin marketing any of its
services or products in such country or territory; provided, that if such business of any such person or entity which otherwise
would be a Restricted Enterprise is immaterial to the other businesses of such person or entity and part of a separate division
or subsidiary from that which you are then employed, then such person or entity shall not be deemed to be a Restricted Enterprise.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD><B><U>Non-Solicitation of Employees</U></B> &ndash; During the Restriction Period, you shall not directly or indirectly, hire,
contact, recruit, induce or solicit (or assist any person to hire, contact, induce or solicit) for employment or other services
any person who is, or within twelve (12) months prior to the date of such hiring, contacting, inducing or solicitation was, an
employee, independent contractor, or consultant of the Company or any of its subsidiaries. For purposes of this Paragraph 14, independent
contractors and consultants refer to such persons, companies, or entities that on or prior to the Termination Date performed services
related to the business of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="image_002.jpg" ALT=""></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0"  STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD><B><U>Non-Solicitation of Customers</U> &ndash;</B> During the Restriction Period, you shall not directly or indirectly, solicit,
contact (including but not limited to e-mail, regular mail, express mail, telephone, fax, and instant message), attempt to contact,
or meet with the Company&rsquo;s current, former, or prospective customers for purposes of offering or accepting goods or services
for Restricted Enterprises or cause any such customer to terminate or diminish their commercial relationship with the Company.
For purposes of this Agreement, a &ldquo;prospective customer&rdquo; is any person or entity with whom the Company is or was engaged
in material communications with respect to potential business transactions at the time of employment termination or six (6) months
prior to date of the Termination Date.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">15.</TD><TD><B><U>Entire Agreement</U> &ndash;</B> This Agreement sets forth the entire agreement and understanding of the parties hereto
with respect to the matters covered hereby and supersedes and replaces any express or implied prior agreement with respect to the
terms of your employment and the termination thereof which you may have had with the Company (including, without limitation, the
Retention Agreement (other than Section 3 thereof, which will remain in full force and effect)). This Agreement may be amended
only by a written document signed by the parties hereto.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">16.</TD><TD><B><U>Voluntary Assent</U></B> &ndash; You affirm that you have read this Agreement, and understand all of its terms, including
the full and final release of claims set forth in Paragraph 3. You further acknowledge that you have voluntarily entered into this
Agreement; that you have not relied upon any representation or statement, written or oral, not set forth in this Agreement; that
the only consideration for signing this Agreement is as set forth herein; and that this document gives you the opportunity and
encourages you to have this Agreement reviewed by your attorney and/or tax advisor.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">17.</TD><TD><B><U>Waiver</U> &ndash;</B> The failure of either party to this Agreement to enforce any of its terms, provisions or covenants
will not be construed as a waiver of the same or of the right of such party to enforce the same. Waiver by either party hereto
of any breach or default by the other party of any term or provision of this Agreement will not operate as a waiver of any other
breach or default.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">18.</TD><TD><B><U>Severability</U></B> &ndash; In the event that any provision of this Agreement is held to be invalid, illegal or unenforceable,
the validity, legality and enforceability of the remainder of this Agreement will not in any way be affected or impaired thereby.
If any provision of this Agreement is held to be excessively broad as to duration, activity or subject, such provision will be
construed by limiting and reducing it so as to be enforceable to the maximum extent allowed by applicable law.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">19.</TD><TD><B><U>Counterparts</U> &ndash;</B> This Agreement may be executed in one or more counterparts, which together will constitute
one and the same agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="image_002.jpg" ALT=""></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0"  STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">20.</TD><TD><B><U>Notices</U> &ndash;</B> All notices, demands, requests or other communications which may be or are required to be given,
served, or sent by a party pursuant to this Agreement shall be in writing and shall be hand delivered (including delivery by courier),
mailed by first-class, registered or certified mail, return-receipt requested, postage prepaid, or transmitted by telegram, telex
or facsimile transmission, addressed as follows:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">If to the
Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Abeona Therapeutics</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">1330 Avenue
of the Americas</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">New York,
NY 10019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Attention:
Kristina Maximenko, HR</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Telephone:
(781) 267-4056</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Email: kmaximenko@abeonatherapeutics.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">If to you:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">At your address
on file with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">Each party may designate by notice
in writing a new address to which any notice, demand, request or communication may thereafter be so given, served or sent</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">21.</TD><TD><B><U>Applicable Law</U></B> - This Agreement shall be governed by the laws of New York without reference to that jurisdiction's
choice of law rules.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">If you have any questions about the matters covered
in this Agreement, please contact me at (203) 747 0604.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Very truly yours,<BR>
<BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Abeona Therapeutics, Inc.<BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">By: <U>&nbsp;&nbsp;/s/ Carsten Thiel</U>_____________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">F. Carsten Thiel, Ph.D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="image_002.jpg" ALT=""></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0"  STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">I hereby agree to the terms and conditions set forth
above. I intend that this Agreement become a binding agreement between me and the Company. I further understand that payment of
the consideration and other benefits described herein is conditioned upon my timely execution, return and non-revocation of this
Agreement and the Final Release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 4in">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><U>/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey
    Davis</FONT></U></TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date &nbsp;<U>10/01/18</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey Davis</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: right">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="image_002.jpg" ALT=""></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0"  STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>ATTACHMENT A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>FINAL RELEASE OF CLAIMS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 94.5pt"></TD><TD STYLE="width: 36pt">1.</TD><TD><B><U>Release</U></B> - In consideration of the severance benefits set forth in the Agreement to which this Final Release of
Claims (the &ldquo;Final Release&rdquo;) is attached, which you acknowledge you would not otherwise be entitled to receive, you
waive, subject to the exceptions specified below, all claims available under federal, state or local law against the Company and
the directors, officers, employees, employee benefit plans and agents of the Company arising out of your employment with the Company
or the termination of that employment, including but not limited to all claims arising under the Americans with Disabilities Act,
the Age Discrimination in Employment Act, the Civil Rights Act of 1991, the Employee Retirement Income Security Act (&ldquo;ERISA&rdquo;),
the Equal Pay Act, the Genetic Information Non-discrimination Act, the Family and Medical Leave Act, Section 1981 of U.S.C, Title
VII of the Civil Rights Act; the New York State Human Rights Law, the New York State Executive Law, the New York State Civil Rights
Law, the retaliation provisions of the New York State Workers' Compensation Law, the New York Labor Law, the New York City Human
Rights Law, and the New York City Administrative Code; as well as wrongful termination claims, breach of contract claims, discrimination
claims, harassment claims, retaliation claims, whistleblower claims (to the fullest extent they may be released under applicable
law), defamation or other tort claims, and claims for attorneys&rsquo; fees and costs.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">The only claims not being waived,
released and discharged by this Final Release are (i) those that relate to your rights and remedies under this Agreement, (ii)
any rights to the indemnification exculpation and/or contribution to which you are entitled as of the date hereof pursuant to the
Company&rsquo;s and its affiliates organizational documents, any indemnification or similar agreement or applicable law (and any
rights under the insurance policies of the Company or its affiliates) and (iii) those that cannot be waived as a matter of applicable
law; any claims you may have to government-sponsored and administered benefits such as unemployment insurance, workers&rsquo; compensation
insurance (excluding claims for retaliation under workers&rsquo; compensation laws), state disability insurance and paid family
leave insurance benefits; and any benefits that vested on or prior to the Separation Date pursuant to a written benefit plan sponsored
by the Company and governed by ERISA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">Nothing in this Final Release prevents
you from filing a charge with, cooperating with, or participating in any proceeding before the Equal Employment Opportunity Commission
or a state fair employment practices agency (except that you acknowledge that you may not recover any monetary benefits in connection
with any such claim, charge or proceeding).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="image_002.jpg" ALT=""></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0"  STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 94.5pt"></TD><TD STYLE="width: 36pt">2.</TD><TD><B><U>Business Expenses and Compensation</U></B> - You acknowledge that you have been reimbursed by the Company for all business
expenses incurred in conjunction with the performance of your employment and that no other reimbursements are owed to you. You
further acknowledge that you have received payment in full for all services rendered in conjunction with your employment by the
Company and that no other compensation is owed to you except as provided in the Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 94.5pt"></TD><TD STYLE="width: 36pt">3.</TD><TD><B><U>Return of Company Property</U></B> - You agree that you have returned all Company property, including but not limited
to keys, ID card, cell phone, PDA, thumb drive, and Company documents and information (either hard copy or electronic) other than
records related solely to your own compensation or benefits. To the extent you have any Company material or information stored
on any personal electronic devices, you represent and warrant that you have destroyed all such information currently known to you
(subject to any litigation preservation directive then in effect) and that you will cooperate with the Company to ensure the return
and permanent deletion of all such material and information discovered in the future.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 94.5pt"></TD><TD STYLE="width: 36pt">4.</TD><TD><B><U>Acknowledgments</U></B> - You acknowledge that you are being provided twenty-one (21) days to consider this Final Release
and that the Company hereby advises you to consult with an attorney of your own choosing prior to signing this Final Release. You
understand that you may revoke this Final Release for a period of seven (7) days after you sign it by notifying me in writing,
and the Final Release shall not be effective or enforceable until the expiration of this seven (7) day revocation period. You understand
and agree that by entering into this Final Release, you are waiving any and all rights or claims you might have under the Age Discrimination
in Employment Act, as amended by the Older Workers Benefit Protection Act, and that you have received consideration beyond that
to which you were previously entitled.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 94.5pt"></TD><TD STYLE="width: 36pt">5.</TD><TD><B><U>Incorporation by Reference</U></B> - This Final Release incorporates by reference, as if set forth fully herein, all
terms and conditions of the September 28, 2018 Agreement between you and the Company, including the recitation of consideration
provided by the Company. By signing this Final Release, you hereby waive, release and forever discharge any and all claims that
may have arisen through the date of your execution of this Final Release. You acknowledge that this Final Release is not intended
to otherwise change, alter or amend any of the terms and conditions of the September 28, 2018 Agreement, for which you received
adequate consideration, and which Agreement remains in full force and effect. You acknowledge and agree that you continue to be
bound by the terms and conditions of the September 28, 2018 Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="image_002.jpg" ALT=""></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0"  STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>I hereby provide this Final Release as of the current date
and acknowledge that the execution of this Final Release is in further consideration of the severance benefits to which I acknowledge
I would not be entitled if I did not sign this Final Release. I intend that this Final Release become a binding agreement between
the Company and me if I do not revoke my acceptance in seven (7) days.&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 15%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 35%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 15%; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; border-bottom: Black 1pt solid">&nbsp;&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; border-bottom: Black 1pt solid">&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey Davis</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">Date</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To be signed and returned within 21 days after the Separation
Date, <B><I><U>but not before</U></I></B> the Separation Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 12; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="image_002.jpg" ALT=""></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0; text-align: left"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !> 0P# 2(  A$! Q$!_\0
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M-1U.?5_%46A0KJ-I#"2;EGL5DM[E, E2S= 1D9[YKK(HHX(DBAC6.- %5$&
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MJ8JE"72]_N9R5JTG"SW2;?KH:WQ:UV_BU>ST^VNIH;7[.)CY3E?,8L1DD=0
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M^E?6XVC.K2Y8;_F9X"M"E5YI[?D?0%%8GAGQ-;>*-/:\M;:YA16VGSTP"?\
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B9W]D+_S_ %__ .!!H_LA?^?Z_P#_  (-%H]_P"\NWXG_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  Z FD# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5SWC.ZNK305>SEECF>YACS$P5B&< @$\#/K70T
MA4,,$ _6KIR49*35[$5(N47%.USSE[_Q+HU\'N)4ED@L+BY,-S*6_=*X*@E
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MK6U]J]BMY!%"EK#+;HI*2DE\$AOPY]L>]2ZGXXU/2UEMYK*U:[BNS \BL?)
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MW'"]P+<RS($56Y!R2>V#FASBNA$JU.#M*1J?:[S_ *!K_P#?U/\ &C[7>?\
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M/\:NT4778+/N4OM=Y_T#7_[^I_C1]KO/^@:__?U/\:NT4778+/N4OM=Y_P!
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MU8@DDDCW2PF%LXVE@?Y5+12;78+!1112&%%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
'!1110!__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
